🔎 Trials Near Me

Domov › Debelost › Montana

Klinične študije za Debelost v Montana

9 študij za Debelost išče udeležence na lokacijah v Montana.

Mesta v Montana

Uradno besedilo študije (angleško)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Mercury Street Medical /ID# 282016, Butte
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07752979

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • Kalispell Regional Medical Center, Kalispell
Vključevanje udeležencevFaza 3
Starost 18–99 · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07037459

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Missoula
Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci
Starost 18–79 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07654374

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Missoula
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284901

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

  • Kailera Clinical Site, Missoula
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT07284979

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Montana Medical Research, Missoula
Vključevanje udeležencevFaza 3
Starost 18–99 · Vsi spoli · Posodobljeno 27. avg. 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Butte
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07784725

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Butte
  • ACCOMPLISH-1 Research Site, Missoula
Vključevanje udeležencevFaza 3
Starost 18–79 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT07654361

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

  • Mercury Street Medical Group, PLLC, Butte
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT07477704

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.